These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24045249)

  • 1. Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.
    Kim CY; Heye T; Bashir MR; Gebhard TA; Merkle EM
    J Comput Assist Tomogr; 2013; 37(5):732-6. PubMed ID: 24045249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gadofosveset trisodium and gadobenate dimeglumine during time-resolved thoracic MR angiography at 3T.
    Frydrychowicz A; Russe MF; Bock J; Stalder AF; Bley TA; Harloff A; Markl M
    Acad Radiol; 2010 Nov; 17(11):1394-400. PubMed ID: 20650665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-pass and steady-state magnetic resonance angiography of the thoracic vasculature using gadofosveset trisodium.
    Naehle CP; Müller A; Willinek WA; Meyer C; Hestermann T; Gieseke J; Schild H; Thomas D
    J Magn Reson Imaging; 2009 Oct; 30(4):809-16. PubMed ID: 19787726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine.
    Klessen C; Hein PA; Huppertz A; Voth M; Wagner M; Elgeti T; Kroll H; Hamm B; Taupitz M; Asbach P
    Invest Radiol; 2007 Sep; 42(9):659-64. PubMed ID: 17700282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging.
    Ahlman MA; Raman FS; Pang J; Zemrak F; Sandfort V; Penzak SR; Fan Z; Liu S; Li D; Bluemke DA
    BMC Cardiovasc Disord; 2016 Mar; 16():58. PubMed ID: 27004532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T.
    Prompona M; Cyran C; Nikolaou K; Bauner K; Reiser M; Huber A
    Acad Radiol; 2010 Jul; 17(7):862-70. PubMed ID: 20399687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents.
    Maki JH; Wang M; Wilson GJ; Shutske MG; Leiner T
    J Magn Reson Imaging; 2009 Nov; 30(5):1085-92. PubMed ID: 19856442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease.
    McGregor R; Vymazal J; Martinez-Lopez M; Neuwirth J; Salgado P; Beregi JP; Peduto A; de la Pena-Almaguer E; Slater GJ; Shamsi K; Parsons EC
    Eur J Radiol; 2008 Feb; 65(2):316-25. PubMed ID: 17499952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: Multicenter intraindividual crossover comparison.
    Schneider G; Pasowicz M; Vymazal J; Seidl Z; Aschauer M; Konopka M; Bilecen D; Iezzi R; Ballarati C
    AJR Am J Roentgenol; 2010 Aug; 195(2):476-85. PubMed ID: 20651208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of gadofosveset-enhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation.
    Michaely HJ; Attenberger UI; Dietrich O; Schmitt P; Nael K; Kramer H; Reiser MF; Schoenberg SO; Walz M
    Invest Radiol; 2008 Sep; 43(9):635-41. PubMed ID: 18708857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium.
    Iezzi R; Soulez G; Thurnher S; Schneider G; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    Eur J Radiol; 2011 Feb; 77(2):358-68. PubMed ID: 19679417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Reduction in Contrast-Enhanced Cervical MR Angiography: Field Strength Dependency of Vascular Signal Intensity, Contrast Administration, and Arteriographic Quality.
    Dehkharghani S; Qiu D; Albin LS; Saindane AM
    AJR Am J Roentgenol; 2015 Jun; 204(6):W701-6. PubMed ID: 26001259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thoracic and abdominal MRA with gadofosveset: influence of injection rate on vessel signal and image quality.
    Nissen JC; Attenberger UI; Fink C; Dietrich O; Rohrer M; Schoenberg SO; Michaely HJ
    Eur Radiol; 2009 Aug; 19(8):1932-8. PubMed ID: 19283385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study.
    Bosch E; Kreitner KF; Peirano MF; Thurnher S; Shamsi K; Parsons EC
    AJR Am J Roentgenol; 2008 Jan; 190(1):179-86. PubMed ID: 18094309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital heart disease: cardiovascular MR imaging by using an intravascular blood pool contrast agent.
    Makowski MR; Wiethoff AJ; Uribe S; Parish V; Botnar RM; Bell A; Kiesewetter C; Beerbaum P; Jansen CH; Razavi R; Schaeffter T; Greil GF
    Radiology; 2011 Sep; 260(3):680-8. PubMed ID: 21613441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose, time-resolved, contrast-enhanced 3D MR angiography in the assessment of the abdominal aorta and its major branches at 3 Tesla.
    Kramer U; Fenchel M; Laub G; Seeger A; Klumpp B; Bretschneider C; Finn JP; Claussen CD; Miller S
    Acad Radiol; 2010 May; 17(5):564-76. PubMed ID: 20171907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0 T: comparison with steady-state free precession technique at 1.5 T.
    Liu X; Bi X; Huang J; Jerecic R; Carr J; Li D
    Invest Radiol; 2008 Sep; 43(9):663-8. PubMed ID: 18708861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose 3D time-resolved magnetic resonance angiography (MRA) of the supraaortic arteries: correlation with high spatial resolution 3D contrast-enhanced MRA.
    Lee YJ; Laub G; Jung SL; Yoo WJ; Kim YJ; Ahn KJ; Kim BS
    J Magn Reson Imaging; 2011 Jan; 33(1):71-6. PubMed ID: 21182123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset).
    Kelle S; Thouet T; Tangcharoen T; Nassenstein K; Chiribiri A; Paetsch I; Schnackenburg B; Barkhausen J; Fleck E; Nagel E
    Med Sci Monit; 2007 Nov; 13(11):CR469-474. PubMed ID: 17968293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadofosveset trisodium-enhanced magnetic resonance angiography of the left atrium--a feasibility study.
    Wagner M; Rief M; Asbach P; Vogtmann T; Huppertz A; Beling M; Butler C; Laule M; Warmuth C; Taupitz M; Hamm B; Lembcke A
    Eur J Radiol; 2010 Aug; 75(2):166-72. PubMed ID: 19464133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.